ArticleMolecular genetics and metabolism reports2026
Spectrum of inherited metabolic disorders diagnosed through newborn screening and symptomatic referrals in Eastern Türkiye.
Article in Molecular genetics and metabolism reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Inherited metabolic disorders (IMDs) are heterogeneous genetic diseases whose observed spectrum is influenced by population characteristics, newborn screening (NBS), and diagnostic pathways.This study aimed to characterize confirmed IMDs diagnosed through NBS and symptomatic referrals at a tertiary center in Eastern Türkiye and estimate the regional burden of selected disorders. Methods: This retrospective study included patients evaluated between September 2022 and September 2024. IMDs were confirmed by biochemical and/or molecular genetic analyses. Population and live-birth data from the defined referral region were used to estimate regional and NBS-based birth prevalence. Results: Among 9603 patients evaluated, 828 (8.6%) had a confirmed IMDs; 580 (70.0%) were identified through NBS, 230 (27.8%) through symptomatic referral, and 18 (2.2%) through family screening. Vitamin and cofactor metabolism (43.8%) and amino acid metabolism disorders (35.7%) predominated. Biotinidase deficiency was the most frequent disorder ( Conclusion: NBS and symptom-based evaluation are complementary diagnostic pathways for IMDs. The observed disease spectrum reflects the influence of screening strategies, while symptomatic referrals reveal broader clinical and genetic heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.